Special Report: Creating a Safer Treatment to Counteract the Effect of Blood Thinners

One Small Cap Biotech Company Seeks to Find Marketable Anticoagulant Reversal Agent That Will Save Lives

The search for viable alternatives to protamine is clearly an important one, but to date it has generated few successes. One prominent new player in the quest is PolyMedix, Inc. (OTC.BB:PYMX), based in Radnor, Pennsylvania. The company has developed novel small molecules, which it has dubbed "heptagonists," that act to reverse the anticoagulant properties of both heparin and its low molecular weight variant. They are designed to be administered whenever bleeding that results from the use of blood thinners is diagnosed.

The company has shown that its heptagonist compounds, including the lead compound known as PMX-60056, exhibits a number of positive characteristics that may make it useful for this purpose.

PolyMedix has completed four clinical studies with PMX-60056, including three studies that were designed to assess efficacy. Their efforts would not represent the first attempt of their kind. The most significant previous attempt to create a marketable anticoagulant reversal agent took place about two decades ago, when Biomarin developed a drug known as heparinase.

A free, full report special report titled: "A Red-Blooded Medical Challenge: Creating a Safer Treatment to Counteract the Effect of Blood Thinners" appears on BiomedReports.com

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can also access that information.

About BioMedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content.

About PolyMedix, Inc.
PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs for the treatment of serious infectious diseases and acute cardiovascular disorders. PolyMedix uses a rational drug design approach to create non-peptide, small-molecule drug candidates. PolyMedix’s lead antibiotic compound, PMX-30063, is currently in Phase 2 clinical trials. PMX-30063 is a small-molecule that mimics the mechanism of action of human host defense proteins, a mechanism that is distinct from currently approved antibiotic drugs and is intended to make bacterial resistance unlikely to develop. PolyMedix plans to develop this compound for serious systemic Staphylococcal infections, including methicillin resistant Staphylococcus aureus (MRSA). PolyMedix’s lead heptagonist compound, PMX-60056, has completed Phase 1 testing and is being developed to reverse the anticoagulant activity of both heparin and low molecular weight heparins (LMWH). PolyMedix believes that PMX-60056 could potentially be a safer and easier to use anticoagulant reversing agent, with broader activity, than the currently approved therapy for reversing heparin and LMWH. In addition to its small molecule therapeutics, PolyMedix has polymeric formulations with the same mechanism of action as PMX-30063, PolyCides™. PolyCides are intended for use in antimicrobial biomaterials applications as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces.

Source: Marketwire